This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
SolGel Technologies (SLGL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for SolGel Technologies (SLGL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
All You Need to Know About SolGel Technologies (SLGL) Rating Upgrade to Strong Buy
by Zacks Equity Research
SolGel Technologies (SLGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Sol-Gel Technologies Ltd. (SLGL) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
SolGel Technologies (SLGL) delivered earnings and revenue surprises of 135% and 414.98%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cue Biopharma (CUE) delivered earnings and revenue surprises of 31.03% and 137.96%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Amphastar Pharmaceuticals (AMPH) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 20.51% and 6.49%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Bausch Health (BHC) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of 10.11% and 2.97%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
SolGel Technologies (SLGL) delivered earnings and revenue surprises of -53.33% and 64.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of 9.09% and 7.81%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Sharecare, Inc. (SHCR) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sharecare (SHCR) delivered earnings and revenue surprises of 0% and 12.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Bausch Health (BHC) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of -21.33% and 1.39%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Generation Bio Co. (GBIO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -29.27% and 5.64%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Supernus Pharmaceuticals (SUPN) Lags Q4 Earnings Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of -95.12% and 6.39%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies
by Zacks Equity Research
Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies are part of the Zacks Industry Outlook article.
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
by Sundeep Ganoria
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, AMPH and SLGL.
Sol-Gel Technologies Ltd. (SLGL) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sol-Gel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 15.38% and 61.68%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Personalis (PSNL) delivered earnings and revenue surprises of 10.71% and 0.29%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sol-Gel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -86.36% and 51.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sol-Gel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -92.31% and 94.60%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Homology Medicines (FIXX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Homology Medicines (FIXX) delivered earnings and revenue surprises of -17.65% and 23.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 92.11% and 6.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Dr. Reddy's, Amphastar Pharmaceuticals and Sol-Gel Technologies
by Zacks Equity Research
Dr. Reddy's, Amphastar Pharmaceuticals and Sol-Gel Technologies have been highlighted in this Industry Outlook article.
3 Generic Drug Stocks to Watch Amid Inflation Pressures
by Sundeep Ganoria
The impact of inflationary headwinds and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and SLGL.
SolGel Technologies Ltd. (SLGL) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -114.29% and 92.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Bausch Health (BHC) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of -17.39% and 2.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Sol-Gel
by Zacks Equity Research
Teva, Dr. Reddy's and Sol-Gel have been highlighted in this Industry Outlook article.